768-06-9

Basic information

• Product Name: N-oxo-1,4-dihydropyrazine-2-carboxamide
• CAS NO: 768-06-9
• Molecular Formula: C₅H₅N₃O₂
• Molecular Weight: 139.1121
• Mol File: 768-06-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 238.3°C at 760 mmHg
• Flash Point: 97.9°C
• Density: 1.49g/cm³
• Vapor Pressure: 0.0428mmHg at 25°C
• Refractive Index: 1.649
• CAS DataBase Reference: N-oxo-1,4-dihydropyrazine-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-oxo-1,4-dihydropyrazine-2-carboxamide(768-06-9)
• EPA Substance Registry System: N-oxo-1,4-dihydropyrazine-2-carboxamide(768-06-9)

Safety Data

• Hazardous Substances Data: 768-06-9(Hazardous Substances Data)

Upstream product

• 6164-79-0 methyl pyrazine-2-carboxylate 

Downstream Products

• 88393-94-6 N-methylpyrazine-2-carboxamide 

Relevant articles and documents

Pentacyanoferrate(II) complex of pyridine-4- and pyrazine-2-hydroxamic acid as source of HNO: investigation of anti-tubercular and vasodilation activities

A pharmacophore design approach, based on the coordination chemistry of an intimate molecular hybrid of active metabolites of pro-drugs, known to release active species upon enzymatic oxidative activation, is devised. This is exemplified by combining two anti-mycobacterial drugs: pyrazinamide (first line) and delamanid (third line) whose active metabolites are pyrazinoic acid (PyzCOOH) and likely nitroxyl (HNO (or NO.)), respectively. Aiming to generate those active species, a hybrid compound was envisaged by coordination of pyrazine-2-hydroxamic acid (PyzCONHOH) with a Na3[FeII(CN)5] moiety. The corresponding pentacyanoferrate(II) complex Na4[FeII(CN)5(PyzCONHO?)] was synthesized and characterized by several spectroscopic techniques, cyclic voltammetry, and DFT calculations. Chemical oxidation of this complex with H2O2 was shown to induce the release of the metabolite PyzCOOH, without the need of the Mycobacterium tuberculosis (Mtb) pyrazinamidase enzyme (PncA). Control experiments show that both H2O2- and N-coordinated pyrazine FeII species are required, ruling out a direct hydrolysis of the hydroxamic acid or an alternative oxidative route through chelation of a metal center by a hydroxamic group. The release of HNO was observed using EPR spectroscopy in the presence of a spin trapping agent. The devised iron metal complex of pyrazine-2-hydroxamic acid was found inactive against an actively growing/non-resistant Mtb strain; however, it showed a strong dose-dependent and reversible vasodilatory activity with mostly lesser toxic effects than the reference drug sodium nitroprussiate, unveiling thus a potential indication for acute or chronic cardiovascular pathology. This is a priori a further indirect evidence of HNO release from this metal complex, standing as a possible pharmacophore model for an alternative vasodilator drug.